Literature DB >> 10051087

T helper cell subset ratios in patients with severe sepsis.

N R Ferguson1, H F Galley, N R Webster.   

Abstract

BACKGROUND: T helper 1 (Thl) lymphocytes produce interferon gamma (IFNgamma), favouring cell mediated immunity; Th2 cells secrete interleukin-4 (IL-4), favouring humoral immunity. Cytokines produced in sepsis may effect Th subset predominance and subsequent immune responses.
METHODS: We measured Th subsets in ten patients with severe sepsis, seven APACHE II score-matched non-septic critically ill control patients, and ten healthy subjects. Mononuclear leukocytes were isolated and Th subsets identified by flow cytometry.
RESULTS: The median (range) Th1/Th2 ratio was 0.46 (0.2-2.5) in patients with sepsis, which was significantly lower than both non-septic controls (median 2.5 (0.2-5.9), p = 0.050) and healthy subjects (median 3.9 (1.2-10.8), p = 0.01).
CONCLUSIONS: In patients with sepsis, Th2 antibody mediated (humoral) immune responses predominate. This type of response may lead to fibroblast activation and ultimately immunosuppression. Modulation of Th cell subset predominance may present a novel therapeutic option in the treatment of severe sepsis.

Entities:  

Mesh:

Year:  1999        PMID: 10051087     DOI: 10.1007/s001340050795

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  35 in total

Review 1.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Jaks, STATs, Cytokines, and Sepsis.

Authors:  Melanie J Scott; Christopher J Godshall; William G Cheadle
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

3.  Loss of signal transducer and activator of transduction 4 or 6 signaling contributes to immune cell morbidity and mortality in sepsis.

Authors:  Grace Y Song; Chun-Shiang Chung; Rebecca J Rhee; William G Cioffi; Alfred Ayala
Journal:  Intensive Care Med       Date:  2005-09-20       Impact factor: 17.440

4.  Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit.

Authors:  Marc Leone; Jacques Albanèse; Franck Garnier; Christophe Sapin; Karine Barrau; Marie-Christine Bimar; Claude Martin
Journal:  Intensive Care Med       Date:  2003-04-09       Impact factor: 17.440

Review 5.  Role of cellular events in the pathophysiology of sepsis.

Authors:  Chandra Bhan; Pankaj Dipankar; Papiya Chakraborty; Pranita P Sarangi
Journal:  Inflamm Res       Date:  2016-07-08       Impact factor: 4.575

6.  Alterations of T helper lymphocyte subpopulations in sepsis, severe sepsis, and septic shock: a prospective observational study.

Authors:  Jia Li; Ming Li; Longxiang Su; Huijuan Wang; Kun Xiao; Jie Deng; Yanhong Jia; Gencheng Han; Lixin Xie
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

7.  Sepsis reconsidered: Identifying novel metrics for behavioral landscape characterization with a high-performance computing implementation of an agent-based model.

Authors:  Chase Cockrell; Gary An
Journal:  J Theor Biol       Date:  2017-07-18       Impact factor: 2.691

8.  Agent-Based Modeling of Systemic Inflammation: A Pathway Toward Controlling Sepsis.

Authors:  Gary An; R Chase Cockrell
Journal:  Methods Mol Biol       Date:  2021

9.  Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock.

Authors:  Jixin Zhong; Ping Yang; Kenjiro Muta; Robert Dong; Mario Marrero; Feili Gong; Cong-Yi Wang
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

10.  Diversity of interferon gamma and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis.

Authors:  Stefanie B Flohé; Hemant Agrawal; Sascha Flohé; Meenakshi Rani; Jörg M Bangen; F Ulrich Schade
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.